LONDON–(BUSINESS WIRE)–#Allergan–The global cervical dystonia therapeutics market 2019-2023 is expected
to post a CAGR of close to 5% during the forecast period, according to
the latest market research report by Technavio.
A key factor driving the growth of the market is expected approval of
late-stage pipeline molecules. Despite the significant research
undertaken over the past several decades, the treatment that is
promising and having fewer side effects is not yet available for the
treatment of cervical dystonia. This is encouraging pharmaceutical
companies to focus on the development of promising therapeutics for the
treatment of cervical dystonia. As the market currently witnessing an
acute lack of more approved therapies, these late-stage pipeline
molecules can tap into this unmet demand from the cervical dystonia
patient pool. Once these molecules are launched over the forecast
period, the global cervical dystonia therapeutics market should witness
strong value growth from these newly launched therapeutics.
This market research report on the global
cervical dystonia therapeutics market 2019-2023 also provides an
analysis of the most important trends expected to impact the market
outlook during the forecast period. Technavio classifies an emerging
trend as a major factor that has the potential to significantly impact
the market and contribute to its growth or decline.
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
In this report, Technavio highlights reimbursement for botulinum
neurotoxin injections as one of the key emerging trends in the global
cervical dystonia therapeutics market:
Global cervical dystonia therapeutic market:
Reimbursement for botulinum neurotoxin injections
Several reimbursement programs are available to help people access the
high-cost botulinum neurotoxin therapy for the treatment of cervical
dystonia. These reimbursement programs help patients with or without
medical insurance to achieve appropriate reimbursement for their
treatment with botulinum toxins. Additionally, the cervical dystonia
fund is dedicated to assist insured patients who cannot afford the
out-of-pocket costs associated with any US FDA approved treatment for
cervical dystonia. Thus, several reimbursement programs aid the eligible
patients for the high-cost botulinum toxins treatment and thus boost the
global cervical dystonia market growth over the forecast period.
“Allergan, the manufacturer of BOTOX, sponsors a comprehensive
reimbursement program called as BOTOX reimbursement solutions program
which assists patients who are receiving Botox injection treatment.
Also, Ipsen CARES program is designed to help patients get access to
disport therapy for the treatment of cervical dystonia. These
reimbursement programs aid the patients,” says a senior analyst at
Technavio for research on infectious and rare diseases.
Global cervical dystonia therapeutics market:
This market research report segments the global cervical dystonia
therapeutics market by product (botulinum toxins and other therapeutics)
and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2018 with a market share of more than
41%, followed by EMEA and APAC respectively. The dominance of the
Americas can be attributed to the expected approval of late-stage
pipeline molecules and increasing awareness about cervical dystonia.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200